Andreas R. Muehler
Grafelfing, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data.
Journal: Expert opinion on investigational drugs
Published: July 16, 2026
Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS).
Journal: Trials
Published: February 04, 2025
Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial.
Journal: Clinical and translational gastroenterology
Published: July 15, 2024
Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: April 25, 2024
Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: April 08, 2024
Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective Modulators.
Journal: ACS chemical biology
Published: November 01, 2022
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
Journal: Clinical pharmacology in drug development
Published: October 03, 2022
Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Journal: Infectious diseases and therapy
Published: June 03, 2022
A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis.
Journal: Annals of clinical and translational neurology
Published: January 28, 2022
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Journal: Viruses
Published: October 07, 2020
Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases.
Journal: World journal of gastrointestinal pathophysiology
Published: July 21, 2020
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
Journal: European journal of drug metabolism and pharmacokinetics
Published: May 04, 2020
Last Updated: 09/26/2026